Moderna’s stock price fell despite reporting higher-than-expected third-quarter revenue. Analysts attributed the decline to concerns about slowing vaccine demand, uncertainty around its respiratory vaccine pipeline, and potential write-downs in the fourth quarter. While some remain optimistic about the company’s long-term potential, the overall outlook for Moderna appears cautious.
Moderna (MRNA) is set to release its third-quarter earnings before the market opens on Thursday, November 7. While analysts anticipate a loss, the focus will be on revenue and the company’s outlook amidst a changing market landscape. This article provides a breakdown of analyst predictions, recent developments, and a look at the latest analyst ratings for MRNA stock.
The RNA therapies market is experiencing explosive growth, driven by advancements in mRNA, siRNA, and antisense oligonucleotide therapies. Over 80 companies are actively developing 100+ RNA therapies across various stages, targeting diseases like cancer, infectious diseases, and genetic disorders. DelveInsight’s report, ‘RNA Therapies Competitive Landscape – 2024’, provides a comprehensive analysis of this dynamic market, highlighting key players, pipeline drugs, and future growth potential.
Moderna’s stock price is climbing after Health Canada approved its updated COVID-19 vaccine, SPIKEVAX, targeting the KP.2 variant. The approval comes as COVID-19 infections are on the rise, highlighting the importance of staying up-to-date with vaccinations.
Factor Bioscience Inc., a biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting. The meeting will be held in from and Factor will deliver seven presentations, representing the company’s most expansive presentation of data to date.
Arcturus Therapeutics is making strides in the treatment of cystic fibrosis, with their ARCT-032 treatment candidate recently receiving orphan drug designation. The treatment has the potential to be highly effective and is expected to generate substantial revenue upon commercialization, similar to Vertex Pharmaceuticals’ Trikafta. Arcturus is also developing a gene therapy for ornithine transcarbamylase deficiency, known as LUNAR-OTC, which is currently in Phase 2 clinical trials. Despite financial challenges, the company has a valuable portfolio of intellectual property and a strong pipeline of therapies. With positive clinical trial results for their cystic fibrosis and OTC therapies, Arcturus Therapeutics has the potential to become a dominant player in these markets.
Moderna has secured a contract with Brazil’s Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. The agreement marks Moderna’s first-time contribution to Brazil’s vaccination efforts. The vaccine is expected to be delivered in the second quarter of 2024.
